The Korean Society of Blood and Marrow Transplantation Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2012
NCT01488253
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

Clinical Trials Committee of The Korean Society of Blood and Marrow Transplantation

Active Ingredients

Drugs in Phase 2 Trials (2)

sirolimus (rapamune) (1 trial)

tacrolimus (prograf) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Accelerated Phase (Phase 2)

Leukemia, Myeloid, Chronic-Phase (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2